Cogent Biosciences, Inc.: Business Overview, Financials & Competitive Analysis
Cogent Biosciences, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Precision oncology player with compelling Phase 3 data and multiple 2026 NDA filings targeting rare, underserved diseases offers significant upside potential. Cogent Biosciences soared 120% after positive Phase 3 PEAK study results for bezuclastinib in imatinib-resistant GIST patients. The company has multiple late-stage programs advancing with recent breakthrough therapy.
What is Cogent Biosciences, Inc.'s industry? Cogent Biosciences, Inc. (cogentbio.com) operates in Biotechnology. AskCyborg classifies Cogent Biosciences, Inc. under Biotechnology in its company registry.
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases, leveraging validated biology to address the true underlying drivers of disease and provide real hope for pa...
Cyborg Score thesis
Precision oncology player with compelling Phase 3 data and multiple 2026 NDA filings targeting rare, underserved diseases offers...
Read the full analyst-debate transcript →Get the Latest Cogent Biosciences, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCogent Biosciences, Inc. Overview
Pro stress-test →Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases, leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients. The company's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V which drives Systemic Mastocytosis, and is also found in gastrointestinal stromal tumors (GIST).
Strategic Profile
Pro stress-test →Bezuclastinib has exhibited promising initial data across all three trials (APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST), including an encouraging safety profile across 600+ patients in single agent and combination dosing. The company submitted a New Drug Application (NDA) for NonAdvSM in December 2025, with NDA submissions for AdvSM on track for 1H 2026 and GIST on track for April 2026.
Competitive Landscape
Pro stress-test →Blueprint Medicines, Kite Pharma, Senti Bio, NexImmune, and Apollomics are among the 77 competitors of Cogent Biosciences. Cogent's focused approach to KIT-driven diseases and its combination therapy strategy differentiate it within the oncology and rare disease precision medicine space, where companies like Blueprint Medicines also target genetically defined cancers.
Industry Context
Cogent Biosciences, Inc. operates in Biotechnology.
Key facts
Founded: 2014 · Headquarters: Waltham, Massachusetts · Employees: 205 · Market cap: $5.66B